Overview
No overview information available.
Indication
用于非髓性恶性肿瘤患者在接受容易引起发热性中性粒细胞减少症的骨髓抑制性抗癌药物治疗时，降低以发热性中性粒细胞减少症为表现的感染发生率。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/04/15 | Phase 2 | Not yet recruiting | |||
2025/04/11 | Phase 1 | Recruiting | |||
2025/03/25 | Phase 1 | Completed | |||
2025/03/04 | Phase 2 | Recruiting | Sun Yat-sen University | ||
2020/07/10 | Phase 3 | Completed | |||
2010/11/10 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Telpegfilgrastim Injection | 国药准字S20230036 | 生物制品 | 注射剂 | 6/30/2023 | |
| Telpegfilgrastim Injection | 国药准字S20230039 | 生物制品 | 注射剂 | 6/30/2023 | |
| Telpegfilgrastim Injection | 国药准字S20230037 | 生物制品 | 注射剂 | 6/30/2023 | |
| Telpegfilgrastim Injection | 国药准字S20230038 | 生物制品 | 注射剂 | 6/30/2023 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.